Prevalence of Perimyocarditis After Covid-19 Vaccine

Hillel Yaffe Medical Center500 enrolled

Overview

The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Perimyocarditis Covid19

Interventions

Laboratory Blood TestsDIAGNOSTIC_TEST

Blood tests to determine liver and kidney functioning, total blood count, and troponin levels

ECGDIAGNOSTIC_TEST

ECG to determine heart rate and functioning

PCRDIAGNOSTIC_TEST

PCR test to determine whether patient has Covid19

Eligibility

Sex: ALLMin age: 16 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients planning Pfizer-BioNTech BNT162b2 vaccination against Covid19 Exclusion Criteria: * Patients infected with Covid19

Locations (1)

Hillel Yaffe Medical Center

Hadera, Israel

RECRUITING

Outcomes

Primary Outcomes

Elevated Troponin

Laboratory blood tests will be taken before and after Covid19 vaccination and compared. Troponin levels above normal range of 0.4 ng/ml will indicate possibility of perimyocarditis and patient will referred for additional testing.

Time frame: 4 weeks

Central Contacts

Elisabeth Mahajna, MA

CONTACT

972-4-7744695 liesma@hy.health.gov.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.